Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Novavax: Clinical Trials & FDA Approval Profile

Novavax (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 0 active protocols (0 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.1%
Median Closed Enrollment vs National (145 pts)1,358 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Novavax
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)0 (0)
Completed vs Stopped Early17 / 4 (19.1%)
Median Closed Actual Enrollment1,358 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Novavax
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05519839A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccinePhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Novavax Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI